GlassScriptPhysician profile
Benjamin S Friday
NPI 1922369123
$3,496.20
in general payments reported to CMS, 2019-2025
25 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $290 · 2021: $444 · 2022: $636 · 2023: $648 · 2024: $595 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $559.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $481.99 | 2021-2025 | |
| Lilly USA, LLC | $323.67 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $316.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $312.56 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $212.53 | 2020-2025 | Veozah |
| Abbott Laboratories | $212.39 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $195.49 | 2019-2025 | |
| Amgen INC. | $181.03 | 2022-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $154.68 | 2022-2025 | |
| Glaxosmithkline, LLC. | $76.48 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.12 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $62.70 | 2022-2024 | |
| Inari Medical, INC. | $59.86 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Dexcom, INC. | $55.21 | 2022-2025 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $47.32 | 2020-2021 | |
| Amarin Pharma, INC. | $43.71 | 2020-2021 | |
| Inspire Medical Systems, INC. | $25.84 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $18.00 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $15.44 | 2021 | |
| Eisai INC. | $15.34 | 2021 | |
| Dynavax Technologies Corporation | $15.26 | 2024 | Heplisav-B |
| Almatica Pharma LLC | $15.23 | 2021 | |
| Merck Sharp & Dohme LLC | $14.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Friday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.